Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Provepharm Life Solutions has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions involve 2 distinct examiners but are contained within 1 distinct art unit. This indicates that while different individuals are reviewing the work, they belong to the same specialized group. The concentration in 1 distinct art unit suggests a consistent technical classification for the pending applications. This structure allows the applicant to focus their resources on a specific administrative group while managing 2 separate examiner relationships.
JAMES WILLIAM ROGERS is the busiest examiner for the company, holding 1 pending office action. With 2 pending office actions and 2 distinct examiners, the work is split evenly between the assigned staff. For the applicant, this means that understanding the specific tendencies of the 2 distinct examiners is a factor for success. The limited scope of 1 pending office action per examiner simplifies the management of the current portfolio. This approach ensures that feedback is gathered from different professional perspectives within the 1 distinct art unit. Consistency in communication within the single art unit is a key strategic advantage.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549378 | STABLE FORMULATIONS OF INDOCYANINE GREEN | ROGERS, JAMES WILLIAM | — |
| 18549369 | STABLE FORMULATIONS OF INDOCYANINE GREEN | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549378 | STABLE FORMULATIONS OF INDOCYANINE GREEN | ROGERS, JAMES WILLIAM | — |
| 18549369 | STABLE FORMULATIONS OF INDOCYANINE GREEN | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18549378 | STABLE FORMULATIONS OF INDOCYANINE GREEN | ROGERS, JAMES WILLIAM | 1618 | §102§103 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18549369 | STABLE FORMULATIONS OF INDOCYANINE GREEN | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProvepharm Life Solutions has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
James William Rogers has the most, with 1 of Provepharm Life Solutions's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
